Durvalumab fails to improve overall survival in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)

Analysis of the KESTREL Phase III trial has reported that durvalumab has failed to meet the primary endpoint of improving overall survival versus chemotherapy plus cetuximab in the first-line treatment of patients with HNSCC whose tumours expressed high levels of PD-L1.

Source:

PharmaTimes